bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on the stock. Baird R W downgraded shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Wells Fargo & Company reduced their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Finally, Barclays reduced their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, bluebird bio currently has a consensus rating of “Hold” and an average price target of $44.60.

bluebird bio Stock Performance

Shares of BLUE opened at $5.15 on Friday. bluebird bio has a 12-month low of $3.56 and a 12-month high of $28.60. The stock has a market cap of $50.42 million, a P/E ratio of -0.14 and a beta of 0.41. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The company has a 50-day moving average of $4.86 and a two-hundred day moving average of $7.29.

Institutional Investors Weigh In On bluebird bio

Several large investors have recently made changes to their positions in BLUE. Geode Capital Management LLC lifted its holdings in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after buying an additional 166,771 shares during the period. State Street Corp grew its stake in bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares in the last quarter. FMR LLC lifted its stake in bluebird bio by 8.1% in the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after acquiring an additional 186,903 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 355,562 shares in the last quarter. Finally, Barclays PLC raised its position in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.